No problem Cuprum. Once approved many insurance companies with cover based on the cost of breast cancer to the economy and maximising early diagnosis alternatives to the Mam. The US market is staggering even if you just look at out of pocket testings for cultural boundaries of mams.
The question of when largely depends on uptake in Australia after NATA. By then they will have many more data to assist in the approval.
The Australian market alone stacks up for a SP many multiples of where it is now.
Ann: BCAL to Present at Bioshares Biotech Summit - Presentation, page-64
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
-0.005(4.17%) |
Mkt cap ! $41.24M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 11.5¢ | $136.3K | 1.129M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 214793 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 24089 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| BDX (ASX) Chart |